Patiromer sorbitex calcium
As of the edition of 20 October 2026, Patiromer sorbitex calcium is a small molecule: marketed, first approved in 2015 (US); US protection ends in 2030.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Veltassa
- First approved
- 21 October 2015 (US)
- Approvals on record
- 5 in 2 regions
- Holder of the most recent approval
- Zeria Pharmaceutical; 2 holders in all
- Registered trials
- 2, 1 stopped early
- Disease areas
- Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
US protection
US protection ends in 2030.
The last listed US drug-substance patent ends in 2030. The application that gives this date is held by Sanofi.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product8 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 8 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Acquired holder | 2021 to now |
| Zeria Pharmaceutical | Applicant | 2024 to now |
| Relypsa | Originator | 2015 to 2021 |